Review
Immunology
Shuang Fan, Wen-Xuan Huo, Yang Yang, Meng-Zhu Shen, Xiao-Dong Mo
Summary: This study reports the updated results of ruxolitinib as treatment for SR-GVHD and compares the efficacy and safety between children and adults. The findings suggest that ruxolitinib is an effective and safe treatment for SR-GVHD, and both children and adults can benefit from it.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Dong Wang, Yin Liu, Xiaoxuan Lai, Jia Chen, Qiao Cheng, Xiao Ma, Zhihong Lin, Depei Wu, Yang Xu
Summary: The study showed that ruxolitinib is potentially a safe and effective treatment for patients with steroid-refractory chronic GVHD, with an overall response rate of 74.3%. The main adverse event was cytopenia. Treatment with ruxolitinib increased the percentage of CD4 cells, decreased the percentages of NK cells and regulatory T cells, and increased the proportion of total B cells.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Hematology
Jiapei Liu, Zhiping Fan, Na Xu, Jieyu Ye, Yanqiu Chen, Ruoyang Shao, Yiming Sun, Qiaoyuan Wu, Qifa Liu, Hua Jin
Summary: This study evaluated the effects of ruxolitinib compared with basiliximab in the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD). The results showed that ruxolitinib had a higher overall response rate and effectively prevented chronic GVHD (cGVHD), leading to improved survival rates.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Jiapei Liu, Zhiping Fan, Na Xu, Jieyu Ye, Yanqiu Chen, Ruoyang Shao, Yiming Sun, Qiaoyuan Wu, Qifa Liu, Hua Jin
Summary: This study retrospectively evaluated the effects of ruxolitinib compared with basiliximab for steroid-refractory acute graft-versus-host disease (SR-aGVHD). The results showed that ruxolitinib had higher overall response and complete response rates, as well as lower incidence of chronic GVHD. Ruxolitinib also improved overall survival and failure-free survival rates. In addition, ruxolitinib significantly reduced the occurrence of EBV viremia. Therefore, ruxolitinib should be recommended for the treatment of SR-aGVHD.
ANNALS OF HEMATOLOGY
(2023)
Article
Oncology
Elisabetta Xue, Francesca Lorentino, Francesca Pavesi, Andrea Assanelli, Jacopo Peccatori, Massimo Bernardi, Consuelo Corti, Fabio Ciceri, Maria Teresa Lupo Stanghellini
Summary: Chronic Graft versus Host Disease (GvHD) is a serious complication of allogeneic hematopoietic stem cell transplant that severely impacts quality of life and long-term survival. Ruxolitinib has been shown to be a safe and effective salvage treatment option for advanced stages of chronic GvHD, with an overall response rate of 59% at three months and 62% at six months. Further prospective analyses on larger cohorts are ongoing to evaluate the durability of response.
Article
Hematology
Sameem Abedin, Nahid Rashid, Mark Schroeder, Rizwan Romee, Mary Nauffal, Muhamad Alhaj Moustafa, Mohamed A. Kharfan-Dabaja, Jeanne Palmer, William Hogan, Mehrdad Hefazi, Samantha Larson, Shernan Holtan, Zachariah DeFilipp, Reena Jayani, Bhagirathbhai Dholaria, Joseph Pidala, Farhad Khimani, Michael R. Grunwald, Candace Butler, Mehdi Hamadani
Summary: Among 307 patients with SR-aGVHD, approximately 1/5 of patients showed resistance or intolerance to Ruxolitinib. The overall response rate to additional therapy was 36% in resistant patients with a median survival of 21 days; while 50% of intolerant patients continued to improve with additional therapy, with a median survival of 50 days. These data provide a baseline for future studies on SR-aGVHD.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Chemistry, Medicinal
Cong Wei, Xiaoting Zhang, Dan Liang, Jilong Yang, Jingwen Du, Chunyan Yue, Lan Deng
Summary: Ruxolitinib has been shown to be a safe and effective treatment for steroid-refractory GVHD in a Chinese population, with high overall response rates in acute GVHD patients and comparable overall survival rates between responders and non-responders in chronic GVHD patients. Common adverse events include cytopenia, cytomegalovirus reactivation, and infections, particularly in patients with acute GVHD.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Dentistry, Oral Surgery & Medicine
Martina Kaurinovic, Konstantina Delli, Ana-Mae E. Jonk, Anouschka Biswana, Carin L. E. Hazenberg, Goda Choi, Marco R. de Groot, Linde M. Morsink, Arjan Vissink, Mar Bellido
Summary: The study aimed to assess the effect of ruxolitinib on the oral mucosa of SR-cGVHD patients with oral involvement. In an observational longitudinal patient study, 53 patients with SR-cGVHD and oral involvement were treated with ruxolitinib. The baseline condition of the oral mucosa was compared to its condition at 4 and 12 weeks after starting ruxolitinib.
CLINICAL ORAL INVESTIGATIONS
(2022)
Article
Chemistry, Medicinal
Wenli Yang, Guanghua Zhu, Maoquan Qin, Zhigang Li, Bin Wang, Jun Yang, Tianyou Wang
Summary: The study found that Ruxolitinib is effective for acute and chronic graft-versus-host disease in children. Patients with chronic GVHD had a higher overall response rate and better prognosis after treatment compared to those with acute GVHD.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Medicine, General & Internal
Robert Zeiser, Nicola Polverelli, Ron Ram, Shahrukh K. Hashmi, Ronjon Chakraverty, Jan Moritz Middeke, Maurizio Musso, Sebastian Giebel, Ant Uzay, Peter Langmuir, Norbert Hollaender, Maanasa Gowda, Tommaso Stefanelli, Stephanie J. Lee, Takanori Teshima, Franco Locatelli
Summary: The study suggests that ruxolitinib can significantly improve overall response, failure-free survival, and symptom response in patients with glucocorticoid-refractory or -dependent chronic graft-versus-host disease (GVHD), although it may increase the incidence of thrombocytopenia and anemia.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Hematology
Garret M. K. Leung, Joycelyn P. Y. Sim, Yu-Yan Hwang, Thomas S. Y. Chan, Albert K. W. Lie, Eric Tse, Yok-Lam Kwong
Summary: The JAK2 inhibitor ruxolitinib has shown efficacy in steroid-resistant/dependent acute and chronic GVHD. A minimum of 6 months of continued ruxolitinib treatment is necessary to maximize benefits. For acute GVHD, superior overall survival and failure-free survival were associated with achieving CR within 28 days, while for chronic GVHD, achieving CR within 1 year was associated with better overall survival and failure-free survival.
ANNALS OF HEMATOLOGY
(2022)
Review
Oncology
Robert Q. Le, Xin Wang, Hongfei Zhang, Hongshan Li, Donna Przepiorka, Jonathon Vallejo, Ruby Leong, Lian Ma, Kirsten B. Goldberg, Richard Pazdur, Marc R. Theoret, Angelo De Claro
Summary: The Food and Drug Administration approved ruxolitinib for the treatment of chronic graft-versus-host disease (cGVHD) after the failure of systemic therapy. Ruxolitinib demonstrated higher response rates and longer duration of response compared to best available therapy (BAT), with manageable adverse reactions.
Article
Hematology
Aliana Meneses Ferreira, Roberta Shcolnik Szor, Vinicius Campos Molla, Maria Cristina Seiwald, Pedro Arruda de Moraes, Ana Rita Brito Medeiros da Fonseca, Erick Menezes Xavier, Mariana Gomes Serpa, Luciana Tucunduva, Yana Novis, Celso Arrais-Rodrigues
Summary: A retrospective analysis of 35 patients with steroid-refractory cGVHD treated with ruxolitinib showed an overall response rate of 89%, with long-term follow-up indicating the drug as a safe and effective option, reducing the need for immunosuppressive therapy in patients.
TRANSPLANTATION AND CELLULAR THERAPY
(2021)
Article
Dermatology
Morgan E. Belina, Timothy A. Driscoll, Sarah K. Blanchard, Adela R. Cardones
Summary: Chronic graft-versus-host disease (cGVHD) of the skin is a serious cause of long-term morbidity and mortality among patients who receive hematopoietic stem cell transplants. There is currently no consensus on second-line therapy for steroid-refractory disease. This case report presents successful treatment of a pediatric patient with severe cGVHD of the skin, nonresponsive to corticosteroids, using a prolonged course of ruxolitinib with minimal side effects.
PEDIATRIC DERMATOLOGY
(2022)
Article
Cell & Tissue Engineering
Maria del Mar Macias-Sanchez, Cynthia Morata-Tarifa, Natividad Cuende, Ana Cardesa-Gil, Maria Angeles Cuesta-Casas, Maria Jesus Pascual-Cascon, Antonia Pascual, Carmen Martin-Calvo, Manuel Jurado, Jose Antonio Perez-Simon, Ildefonso Espigado, Sebastian Garzon Lopez, Gloria Carmona Sanchez, Rosario Mata-Alcazar-Caballero, Rosario Sanchez-Pernaute
Summary: Clinical trials using MSC therapy for GVHD have shown promising results, with a high overall response rate in patients. For patients with acute GVHD, age at the time of HSCT was found to be the only predictor inversely correlated with survival. Adverse events during treatment were reported but all resolved without long-term consequences, demonstrating the safety of MSC therapy.
STEM CELLS TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Pankaj Ahluwalia, Ashis K. Mondal, Meenakshi Ahluwalia, Nikhil S. Sahajpal, Kimya Jones, Yasmeen Jilani, Gagandeep K. Gahlay, Amanda Barrett, Vamsi Kota, Amyn M. Rojiani, Ravindra Kolhe
Summary: Understanding the tumor microenvironment is crucial for personalized cancer treatment. This study identified a four-gene prognostic signature for colorectal cancer and found associations with immune cell infiltration and immunosuppression.
Article
Oncology
Ajibade Ashaye, Caitlin Thomas, Mehul Dalal, Vamsi Kota, Nicolas Krucien, Maria Sae-Hau, Elisa Weiss, Scott Campbell, Kevin Marsh
Summary: This study examines the preferences of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for tyrosine kinase inhibitors combined with chemotherapy as first-line treatment. The results show that while overall survival (OS) is the most important factor for patients, they are willing to tolerate a small increase in cardiovascular risk for additional months of OS. The study highlights the importance of shared decision making in selecting treatments for Ph+ ALL.
Article
Hematology
Kathryn E. Flynn, Ehab Atallah, Li Lin, Neil P. Shah, Richard T. Silver, Richard A. Larson, Javier Panilla-Ibarz, James E. Thompson, Vivian G. Oehler, Jerald P. Radich, Vamsi Kota, Michael J. Mauro, Charles A. Schiffer, Jorge Cortes, Kevin P. Weinfurt
Summary: Discontinuation of TKI therapy in optimally treated CML patients can result in increased pain, although there is limited agreement between physician-reported adverse events and patient-reported pain. Resuming TKI treatment for withdrawal syndrome may be necessary for some, but alternative approaches to manage pain should be considered.
Article
Oncology
Tim H. Brummendorf, Jorge E. Cortes, Dragana Milojkovic, Carlo Gambacorti-Passerini, Richard E. Clark, Philipp le Coutre, Valentin Garcia-Gutierrez, Charles Chuah, Vamsi Kota, Jeffrey H. Lipton, Philippe Rousselot, Michael J. Mauro, Andreas Hochhaus, Rafael Hurtado Monroy, Eric Leip, Simon Purcell, Anne Yver, Andrea Viqueira, Michael W. Deininger
Summary: This study reports the efficacy and safety of bosutinib in newly diagnosed chronic phase chronic myeloid leukemia (CML) patients after five years of follow-up. Bosutinib showed higher major molecular response rates compared to imatinib, with consistent benefits across different risk groups. The study supports the use of 400-mg once-daily bosutinib as standard-of-care in these patients.
Article
Microbiology
Viviana Simon, Vamsi Kota, Ryan F. Bloomquist, Hannah B. Hanley, David Forgacs, Savita Pahwa, Suresh Pallikkuth, Loren G. Miller, Joanna Schaenman, Michael R. Yeaman, David Manthei, Joshua Wolf, Aditya H. Gaur, Jeremie H. Estepp, Komal Srivastava, Juan Manuel Carreno, Frans Cuevas, Ali H. Ellebedy, Aubree Gordon, Riccardo Valdez, Sarah Cobey, Elaine F. Reed, Ravindra Kolhe, Paul G. Thomas, Stacey Schultz-Cherry, Ted M. Ross, Florian Krammer
Summary: This study provides a detailed description of the PARIS/SPARTA cohorts, harmonized assays, and analysis methods, as well as case definitions for SARS-CoV-2 infection and reinfection. Determining reinfection rates and correlates of protection against SARS-CoV-2 infection induced by both natural infection and vaccination is of high significance for the prevention and control of COVID-19.
Article
Pathology
Nikhil S. Sahajpal, Ashis K. Mondal, Tatiana Tvrdik, Jennifer Hauenstein, Huidong Shi, Kristin K. Deeb, Debra Saxe, Alex R. Hastie, Alka Chaubey, Natasha M. Savage, Vamsi Kota, Ravindra Kolhe
Summary: This study demonstrates the utility of optical genome mapping (OGM) as a new technology for better characterization of hematological malignancies, including revealing the genetic complexity of tumors, with high technical performance and concordance. OGM has the potential to be a first-tier cytogenomic test for hematologic malignancies.
JOURNAL OF MOLECULAR DIAGNOSTICS
(2022)
Article
Oncology
Nidhi Mehra, Armon Varmeziar, Xinyu Chen, Olivia Kronick, Rachel Fisher, Vamsi Kota, Cassie S. Mitchell
Summary: This study comprehensively assessed the relationship between TKIs and adverse events using text mining and machine learning methods. It provided new insights into the breadth of adverse events caused by TKI usage and made recommendations for proactive monitoring and personalized drug selection.
Article
Medicine, Research & Experimental
Vamsi Kota, Augustina Ogbonnaya, Eileen Farrelly, Bridgette Kanz Schroader, Aditya Raju, Fjoralba Kristo, Mehul Dalal
Summary: Patients with higher-risk MDS who transformed to AML had significantly higher healthcare resource utilization and costs compared to those whose disease did not transform, highlighting the important need for treatments that prevent or delay transformation.
ADVANCES IN THERAPY
(2022)
Article
Oncology
Talha Badar, Mark R. Litzow, Rory M. Shallis, Anand Patel, Antoine N. Saliba, Madelyn Burkart, Jan P. Bewersdorf, Maximilian Stahl, Guilherme Sacchi De Camargo Correia, Guru Subramanian Guru Murthy, Yasmin Abaza, Adam Duvall, Danielle Bradshaw, Vamsi Kota, Shira Dinner, Aaron D. Goldberg, Neil Palmisiano, Aref Al Kali, Ehab Atallah
Summary: Although the clinical outcomes of TP53-mutated AML patients are generally poor, some patients eligible for curative-intent therapies may have better outcomes. This multicenter, retrospective study found racial disparities among TP53-mutated AML patients, with differences in treatment and outcomes between non-Hispanic White (NHW) and non-Hispanic Black (NHB) patients.
Article
Oncology
Pau Montesinos, Vamsi Kota, Joseph Brandwein, Pierre Bousset, Rebecca J. Benner, Erik Vandendries, Ying Chen, Mary Frances McMullin
Summary: This study aimed to evaluate the effects of fractionated dosing of gemtuzumab ozogamicin (GO) on the QT interval, pharmacokinetics (PK), and immunogenicity in patients with relapsed/refractory acute myeloid leukemia (AML). The results showed that fractionated dosing of GO is not associated with a clinically significant risk of QT interval prolongation in AML patients, and the presence of antidrug antibodies (ADAs) is not related to potential safety issues.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2023)
Article
Oncology
Anda Gershon, Esprit Ma, Tao Xu, Melissa Montez, Kiran Naqvi, Grace Ku, Wendy Wei-Han Cheng, Evelyn M. Flahavan, Vamsi Kota, Daniel R. Greenwald
Summary: This retrospective cohort study examined the early real-world treatment experience of patients with newly diagnosed acute myeloid leukemia (AML) receiving venetoclax + hypomethylating agents (HMAs) or HMA monotherapy. The study found that venetoclax + HMAs showed better real-world outcomes compared to HMA monotherapy in a predominantly community-based database.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Article
Oncology
Talha Badar, Ehab Atallah, Rory Shallis, Antoine N. Saliba, Anand Patel, Jan P. Bewersdorf, Justin Grenet, Maximilian Stahl, Adam Duvall, Madelyn Burkart, Neil Palmisiano, Danielle Bradshaw, Michal Kubiak, Shira Dinner, Aaron D. Goldberg, Yasmin Abaza, Guru Subramanian Guru Murthy, Vamsi Kota, Mark R. Litzow
Summary: We conducted a multi-center study to analyze factors predicting survival among TP53-mutated (m) AML patients receiving allogeneic hematopoietic stem cell transplant (allo-HSCT) in the recent era. The results showed that complete remission at day 100 post allo-HSCT and occurrence of chronic GVHD are significant predictors for better event-free survival (EFS) and overall survival (OS). Our findings suggest that allo-HSCT offers the best opportunity for long-term improvement in TP53m AML patients.
Article
Virology
Ashutosh Vashisht, Pankaj Ahluwalia, Ashis K. Mondal, Harmanpreet Singh, Nikhil S. Sahajpal, Sadanand Fulzele, Vamsi Kota, Gagandeep K. Gahlay, Ravindra Kolhe
Summary: The emergence of COVID-19 has resulted in significant morbidity and mortality, with around seven million deaths worldwide as of February 2023. Age and sex are risk factors associated with severe symptoms in COVID-19, but there is limited research on sex differences in SARS-CoV-2 infection. This study explores sex-specific molecular factors in mouse and human datasets to identify potential links with the SARS-CoV-2 host receptors ACE2 and TMPRSS2 and highlights the importance of assessing sex differences for optimal treatment and vaccination strategies.
Article
Oncology
Nikhil Shri Sahajpal, Ashis K. Mondal, Harmanpreet Singh, Ashutosh Vashisht, Sudha Ananth, Daniel Saul, Alex R. Hastie, Benjamin Hilton, Barbara R. DuPont, Natasha M. Savage, Vamsi Kota, Alka Chaubey, Jorge E. Cortes, Ravindra Kolhe
Summary: The current genetic testing of myeloid cancers lacks resolution and is limited to specific genomic regions/genes. This study used a combination of high-resolution cytogenetic technology and next-generation sequencing to obtain a comprehensive genomic profile of these tumors. The combinatorial approach identified new genetic alterations and clinically relevant alterations in previously negative cases.
Article
Multidisciplinary Sciences
Nikhil S. Sahajpal, Ashis K. Mondal, Sudha Ananth, Allan Njau, Kimya Jones, Pankaj Ahluwalia, Eesha Oza, Ted M. Ross, Vamsi Kota, Arvind Kothandaraman, Sadanand Fulzele, Madhuri Hegde, Alka Chaubey, Amyn M. Rojiani, Ravindra Kolhe
Summary: The study presents the clinical validation of a multiplex-PCR assay for the simultaneous detection of SARS-CoV-2, influenza A, and influenza B viruses. The results showed that the multiplex assay had a higher detection rate for SARS-CoV-2 compared to a SARS-specific assay. The study highlights the feasibility of implementing this assay without disrupting the existing laboratory workflow.
SCIENTIFIC REPORTS
(2022)
